Loading...
Market
At what phase will PS757 have successful clinical trials by August 5, 2025?
2
Resolution / Starting Odds
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
None • 25%
Clinical trial registries and announcements from the research team
Story
New Compound PS757 Fights Drug-Resistant Bacteria, Guides GmPcide Development
Aug 5, 2024, 07:05 AM
Researchers have discovered a new compound, PS757, that shows promise in fighting flesh-eating and other drug-resistant bacteria. This revolutionary dual-action antibiotic makes bacterial resistance nearly impossible by damaging the cell membranes of the bacteria. The findings, which were tested on Gram-positive pathogens in mice, are expected to guide the development and optimization of a new class of antibiotics called GmPcide compounds. The discovery was announced on August 4 and further detailed on August 5.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%